Many Australian HER2+ metastatic breast cancer (MBC) patients with bone metastases do not receive a bone modifying agent (BMA) and there is significant practice variation among clinicians when it comes to dosing, interval schedules and de-escalating the therapy, registry data shows. The prospective review of patient data from the HER2+ MBC registry, TABITHA, is the ...
Spotlight on underuse of bone modifying agents in cancer patients
By Mardi Chapman
25 May 2021